• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Pfizer pivots from early-stage rare disease R&D, shifting to external innovation and...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 06, 2023 at 10:32: AM
via Pfizer is stepping back from early-stage rare disease R&D. After reviewing its portfolio, the Big Pharma has begun “exploring externalization opportunities for a number of highly innovative, niche programs” as part of a rethink of its approach to orphan indications.

article source
 

<



Similar threads

cafead
ESMO: Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
Replies
0
Views
5
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Valneva and Pfizer report positive data from trial of Lyme disease vaccine booster
Replies
0
Views
15
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Vaxcyte&#039;s &#039;stunning&#039; 31-valent pneumococcal vaccine win against Pfizer&#039;s Prevnar 20 has analysts thinking big
Replies
0
Views
19
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote